Zhenyu Xu Sells 2,400 Shares of SOPHiA GENETICS (NASDAQ:SOPH) Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Zhenyu Xu sold 2,400 shares of SOPHiA GENETICS stock in a transaction on Tuesday, April 7th. The stock was sold at an average price of $4.87, for a total transaction of $11,688.00. Following the transaction, the insider directly owned 644,952 shares of the company’s stock, valued at approximately $3,140,916.24. This trade represents a 0.37% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Zhenyu Xu also recently made the following trade(s):

• On Monday, April 6th, Zhenyu Xu sold 2,700 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.85, for a total transaction of $13,095.00.
• On Thursday, March 19th, Zhenyu Xu sold 608 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.78, for a total transaction of $2,906.24.

SOPHiA GENETICS Stock Performance

SOPH stock traded down $0.01 during midday trading on Wednesday, reaching $4.89. 64,929 shares of the company were exchanged, compared to its average volume of 188,371. The company has a debt-to-equity ratio of 1.01, a current ratio of 1.96 and a quick ratio of 1.84. The business has a 50-day moving average price of $4.78 and a two-hundred day moving average price of $4.68. SOPHiA GENETICS SA has a one year low of $2.58 and a one year high of $5.70. The firm has a market capitalization of $334.64 million, a price-to-earnings ratio of -9.58 and a beta of 1.04.

SOPHiA GENETICS (NASDAQ:SOPH) last released its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.08). SOPHiA GENETICS had a negative return on equity of 50.60% and a negative net margin of 44.22%.The company had revenue of $21.71 million for the quarter, compared to the consensus estimate of $21.20 million. Equities research analysts forecast that SOPHiA GENETICS SA will post -0.96 EPS for the current year.

Wall Street Analysts Forecast Growth

SOPH has been the subject of a number of research analyst reports. Guggenheim lifted their price objective on shares of SOPHiA GENETICS from $6.00 to $7.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Thursday, January 22nd. Finally, BTIG Research reissued a “buy” rating and issued a $7.00 target price on shares of SOPHiA GENETICS in a research report on Tuesday, March 3rd. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $7.00.

Institutional Investors Weigh In On SOPHiA GENETICS

Institutional investors have recently modified their holdings of the business. Savvy Advisors Inc. bought a new stake in shares of SOPHiA GENETICS in the third quarter valued at about $48,000. Squarepoint Ops LLC bought a new stake in shares of SOPHiA GENETICS in the third quarter valued at about $49,000. Perkins Capital Management Inc. bought a new stake in shares of SOPHiA GENETICS in the fourth quarter valued at about $49,000. Quadrature Capital Ltd bought a new stake in shares of SOPHiA GENETICS in the fourth quarter valued at about $54,000. Finally, XTX Topco Ltd bought a new stake in shares of SOPHiA GENETICS in the fourth quarter valued at about $55,000. Institutional investors own 31.59% of the company’s stock.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.